| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2006.
NEWS |
U.S. Girls To Receive HPV Vaccine but Picture Unclear on Potential Worldwide Use, Acceptance
| The first 150 words of the full text of this article appear below. |
With an air that medical history was being made, a government committee unanimously recommended that U.S. girls ages 11 and 12 receive a vaccine that prevents infection by the most common strains of the human papilloma virus (HPV), which accounts for 70% of cervical cancer.
The vote approves the first cancer vaccine ever added to the Centers for Disease Control and Prevention's recommendations, and it represents a significant advance in prevention care, said Jon S. Abramson, M.D., chair of the agency's Advisory Committee on Immunization Practices (ACIP).
"This really is the first vaccine developed specifically to prevent cancer, and the world has been watching to see what we would do," said Abramson, chair of the department of pediatrics at Wake Forest University School of Medicine.
Several other countries have already approved the vaccine, including Mexico and Australia. But these decisions don't resolve questions about whether the vaccine will be widely
Helping Those Who Need It Most
The Question of Cost and Priority
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Outterson and A. S. Kesselheim Market-Based Licensing For HPV Vaccines In Developing Countries Health Aff., January 1, 2008; 27(1): 130 - 139. [Abstract] [Full Text] [PDF]
|
|